News: Halozyme Therapeutics Inc (HALO.A)
7.43USD
23 May 2013
$0.27 (+3.79%)
$7.16
$6.82
$7.50
$6.82
5,800
11,628
$9.88
$3.92
Fri, Mar 22 2013
BRIEF-Halozyme Therapeutics shares up 27 pct in heavy volume
NEW YORK, March 22 - Halozyme Therapeutics Inc : * Shares extend advance in heavy volume, up 27 percent
BRIEF-Halozyme Therapeutics shares rise 21.2 percent in premarket trade
NEW YORK, Dec 21 - Halozyme Therapeutics Inc : * Shares rise 21.2 percent in premarket trade
Press Releases
- Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
- Halozyme Reports Third Quarter 2012 Financial Results
- Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
- Halozyme to Host Third Quarter Financial Results Conference Call
- Halozyme Therapeutics to Host Analyst / Investor Meeting on October 2nd in New York
- ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
- Halozyme Reports Second Quarter 2012 Financial Results
- Halozyme to Host Second Quarter Financial Results Conference Call
- Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
- Halozyme's Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
